We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · May 05, 2022

Durvalumab Alone or Combined With Oleclumab or Monalizumab for Patients With Unresectable, Stage III NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol 2022 Apr 22;[EPub Ahead of Print], RS Herbst, M Majem, F Barlesi, E Carcereny, Q Chu, I Monnet, A Sanchez-Hernandez, S Dakhil, DR Camidge, L Winzer, Y Soo-Hoo, ZA Cooper, R Kumar, J Bothos, C Aggarwal, A Martinez-Marti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading